Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
EDQM
0
USP
0
JP
0
Others
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
API SUPPLIERS
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 25698
Submission : 2011-12-30
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 22163
Submission : 2008-10-27
Status : Inactive
Type : II
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 22163
Submission : 2008-10-27
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 25698
Submission : 2011-12-30
Status : Inactive
Type : II
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
About the Company : BIOTECHNICA DWC LLC has carved a niche for itself in providing value added compliance, regulatory qualification, project management and GDP guidance services to pharma companies al...
About the Company : Kexing Biopharmaceuticals is a forward-thinking biopharmaceutical company primarily dedicated to research and development (R&D), manufacturing, and sales of recombinant protein the...
About the Company : KinBio is a rapidly growing biopharmaceutical company based in Rehovot, Israel, with its main focus on developing needed therapies as well as offering a wide range of CDMO services...
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]South Africa
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Dossiers
Regulatory Info :
Registration Country : Thailand
RECOMBINANT HUMAN ERYTHROPOIETIN
Brand Name : Hema-Plus
Dosage Form : Solution For Injection
Dosage Strength : 4000IU/1ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Thailand
Packaging :
Regulatory Info :
RECOMBINANT HUMAN ERYTHROPOIETIN
Dosage : Solution For Injection
Dosage Strength : 4000IU/1ML
Brand Name : Hema-Plus
Approval Date :
Application Number :
Registration Country : Thailand
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Regulatory FDF Prices
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Annual Reports
Main Therapeutic Indication : Hematology
Currency : USD
2019 Revenue in Millions : 270
2018 Revenue in Millions : 297
Growth (%) : -9
Main Therapeutic Indication : Hematology
Currency : USD
2020 Revenue in Millions : 598
2019 Revenue in Millions : 867
Growth (%) : -31
Main Therapeutic Indication : Hematology
Currency : USD
2020 Revenue in Millions : 552
2019 Revenue in Millions : 790
Growth (%) : -30
Main Therapeutic Indication : Hematology
Currency : USD
2020 Revenue in Millions : 266
2019 Revenue in Millions : 292
Growth (%) : -9
Main Therapeutic Indication : Hematology
Currency : USD
2021 Revenue in Millions : 521
2020 Revenue in Millions : 598
Growth (%) : -13
Main Therapeutic Indication : Hematology
Currency : USD
2021 Revenue in Millions : 479
2020 Revenue in Millions : 552
Growth (%) : -13
Main Therapeutic Indication : Hematology
Currency : USD
2022 Revenue in Millions : 506
2021 Revenue in Millions : 521
Growth (%) : -3
Main Therapeutic Indication : Blood Related Disorders
Currency : USD
2015 Revenue in Millions : 2,031
2014 Revenue in Millions : 1,856
Growth (%) : -9%
Main Therapeutic Indication : Blood Related Disorders
Currency : USD
2014 Revenue in Millions : -9.20%
2013 Revenue in Millions :
Growth (%) :
Main Therapeutic Indication : Blood Disorders
Currency : USD
2017 Revenue in Millions : 1,096
2016 Revenue in Millions : 1,282
Growth (%) : -15
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
ABOUT THIS PAGE
